The Antisense and RNAi Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Antisense and RNAi Therapeutics market size is estimated to be worth US$ 1321.4 million in 2021 and is forecast to a readjusted size of USD 1893.4 million by 2028 with a CAGR of 5.3% during review period. Hospital accounting for % of the Antisense and RNAi Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While RNA Interference segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Antisense and RNAi Therapeutics include Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, and Silence Therapeutics, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Antisense and RNAi Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- RNA Interference
- Antisense RNA
Market segment by Application, can be divided into
- Hospital
- Clinic
Market segment by players, this report covers
- Tekmira Pharmaceuticals
- Arbutus Biopharma
- Alnylam Pharmaceuticals
- Antisense Therapeutics
- Silence Therapeutics
- Isis Pharmaceuticals
- Sirnaomics
- Santaris
- Roche
Market segment by regions, regional analysis covers
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Antisense and RNAi Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Antisense and RNAi Therapeutics, with revenue, gross margin and global market share of Antisense and RNAi Therapeutics from 2019 to 2022.
Chapter 3, the Antisense and RNAi Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Antisense and RNAi Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Antisense and RNAi Therapeutics research findings and conclusion, appendix and data source.
Global Antisense and RNAi Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Antisense and RNAi Therapeutics
1.2 Classification of Antisense and RNAi Therapeutics by Type
1.2.1 Overview: Global Antisense and RNAi Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Type in 2021
1.2.3 RNA Interference
1.2.4 Antisense RNA
1.3 Global Antisense and RNAi Therapeutics Market by Application
1.3.1 Overview: Global Antisense and RNAi Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Antisense and RNAi Therapeutics Market Size & Forecast
1.5 Global Antisense and RNAi Therapeutics Market Size and Forecast by Region
1.5.1 Global Antisense and RNAi Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Antisense and RNAi Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Antisense and RNAi Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Antisense and RNAi Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Antisense and RNAi Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Antisense and RNAi Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Antisense and RNAi Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Antisense and RNAi Therapeutics Market Drivers
1.6.2 Antisense and RNAi Therapeutics Market Restraints
1.6.3 Antisense and RNAi Therapeutics Trends Analysis
2 Company Profiles
2.1 Tekmira Pharmaceuticals
2.1.1 Tekmira Pharmaceuticals Details
2.1.2 Tekmira Pharmaceuticals Major Business
2.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
2.1.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Tekmira Pharmaceuticals Recent Developments and Future Plans
2.2 Arbutus Biopharma
2.2.1 Arbutus Biopharma Details
2.2.2 Arbutus Biopharma Major Business
2.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Product and Solutions
2.2.4 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Arbutus Biopharma Recent Developments and Future Plans
2.3 Alnylam Pharmaceuticals
2.3.1 Alnylam Pharmaceuticals Details
2.3.2 Alnylam Pharmaceuticals Major Business
2.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
2.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.4 Antisense Therapeutics
2.4.1 Antisense Therapeutics Details
2.4.2 Antisense Therapeutics Major Business
2.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Product and Solutions
2.4.4 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Antisense Therapeutics Recent Developments and Future Plans
2.5 Silence Therapeutics
2.5.1 Silence Therapeutics Details
2.5.2 Silence Therapeutics Major Business
2.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Product and Solutions
2.5.4 Silence Therapeutics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Silence Therapeutics Recent Developments and Future Plans
2.6 Isis Pharmaceuticals
2.6.1 Isis Pharmaceuticals Details
2.6.2 Isis Pharmaceuticals Major Business
2.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
2.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Isis Pharmaceuticals Recent Developments and Future Plans
2.7 Sirnaomics
2.7.1 Sirnaomics Details
2.7.2 Sirnaomics Major Business
2.7.3 Sirnaomics Antisense and RNAi Therapeutics Product and Solutions
2.7.4 Sirnaomics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Sirnaomics Recent Developments and Future Plans
2.8 Santaris
2.8.1 Santaris Details
2.8.2 Santaris Major Business
2.8.3 Santaris Antisense and RNAi Therapeutics Product and Solutions
2.8.4 Santaris Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Santaris Recent Developments and Future Plans
2.9 Roche
2.9.1 Roche Details
2.9.2 Roche Major Business
2.9.3 Roche Antisense and RNAi Therapeutics Product and Solutions
2.9.4 Roche Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Roche Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Antisense and RNAi Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Antisense and RNAi Therapeutics Players Market Share in 2021
3.2.2 Top 10 Antisense and RNAi Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Antisense and RNAi Therapeutics Players Head Office, Products and Services Provided
3.4 Antisense and RNAi Therapeutics Mergers & Acquisitions
3.5 Antisense and RNAi Therapeutics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Antisense and RNAi Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Antisense and RNAi Therapeutics Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Antisense and RNAi Therapeutics Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
6.2 North America Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
6.3 North America Antisense and RNAi Therapeutics Market Size by Country
6.3.1 North America Antisense and RNAi Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
7.2 Europe Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
7.3 Europe Antisense and RNAi Therapeutics Market Size by Country
7.3.1 Europe Antisense and RNAi Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region
8.3.1 Asia-Pacific Antisense and RNAi Therapeutics Revenue by Region (2017-2028)
8.3.2 China Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
9.2 South America Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
9.3 South America Antisense and RNAi Therapeutics Market Size by Country
9.3.1 South America Antisense and RNAi Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country
10.3.1 Middle East & Africa Antisense and RNAi Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Antisense and RNAi Therapeutics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Antisense and RNAi Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Antisense and RNAi Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Antisense and RNAi Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Antisense and RNAi Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. Tekmira Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Tekmira Pharmaceuticals Major Business
Table 8. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 9. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Arbutus Biopharma Corporate Information, Head Office, and Major Competitors
Table 11. Arbutus Biopharma Major Business
Table 12. Arbutus Biopharma Antisense and RNAi Therapeutics Product and Solutions
Table 13. Arbutus Biopharma Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 15. Alnylam Pharmaceuticals Major Business
Table 16. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 17. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Antisense Therapeutics Corporate Information, Head Office, and Major Competitors
Table 19. Antisense Therapeutics Major Business
Table 20. Antisense Therapeutics Antisense and RNAi Therapeutics Product and Solutions
Table 21. Antisense Therapeutics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Silence Therapeutics Corporate Information, Head Office, and Major Competitors
Table 23. Silence Therapeutics Major Business
Table 24. Silence Therapeutics Antisense and RNAi Therapeutics Product and Solutions
Table 25. Silence Therapeutics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Isis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Isis Pharmaceuticals Major Business
Table 28. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 29. Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Sirnaomics Corporate Information, Head Office, and Major Competitors
Table 31. Sirnaomics Major Business
Table 32. Sirnaomics Antisense and RNAi Therapeutics Product and Solutions
Table 33. Sirnaomics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Santaris Corporate Information, Head Office, and Major Competitors
Table 35. Santaris Major Business
Table 36. Santaris Antisense and RNAi Therapeutics Product and Solutions
Table 37. Santaris Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Roche Corporate Information, Head Office, and Major Competitors
Table 39. Roche Major Business
Table 40. Roche Antisense and RNAi Therapeutics Product and Solutions
Table 41. Roche Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Antisense and RNAi Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Antisense and RNAi Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Antisense and RNAi Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Antisense and RNAi Therapeutics Players Head Office, Products and Services Provided
Table 46. Antisense and RNAi Therapeutics Mergers & Acquisitions in the Past Five Years
Table 47. Antisense and RNAi Therapeutics New Entrants and Expansion Plans
Table 48. Global Antisense and RNAi Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 49. Global Antisense and RNAi Therapeutics Revenue Share by Type (2017-2022)
Table 50. Global Antisense and RNAi Therapeutics Revenue Forecast by Type (2023-2028)
Table 51. Global Antisense and RNAi Therapeutics Revenue by Application (2017-2022)
Table 52. Global Antisense and RNAi Therapeutics Revenue Forecast by Application (2023-2028)
Table 53. North America Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Antisense and RNAi Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Antisense and RNAi Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Antisense and RNAi Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Antisense and RNAi Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Antisense and RNAi Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Antisense and RNAi Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Antisense and RNAi Therapeutics Picture
Figure 2. Global Antisense and RNAi Therapeutics Revenue Market Share by Type in 2021
Figure 3. RNA Interference
Figure 4. Antisense RNA
Figure 5. Antisense and RNAi Therapeutics Revenue Market Share by Application in 2021
Figure 6. Hospital Picture
Figure 7. Clinic Picture
Figure 8. Global Antisense and RNAi Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 9. Global Antisense and RNAi Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2017-2028)
Figure 11. Global Antisense and RNAi Therapeutics Revenue Market Share by Region in 2021
Figure 12. North America Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 13. Europe Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Asia-Pacific Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. South America Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Middle East and Africa Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Antisense and RNAi Therapeutics Market Drivers
Figure 18. Antisense and RNAi Therapeutics Market Restraints
Figure 19. Antisense and RNAi Therapeutics Market Trends
Figure 20. Tekmira Pharmaceuticals Recent Developments and Future Plans
Figure 21. Arbutus Biopharma Recent Developments and Future Plans
Figure 22. Alnylam Pharmaceuticals Recent Developments and Future Plans
Figure 23. Antisense Therapeutics Recent Developments and Future Plans
Figure 24. Silence Therapeutics Recent Developments and Future Plans
Figure 25. Isis Pharmaceuticals Recent Developments and Future Plans
Figure 26. Sirnaomics Recent Developments and Future Plans
Figure 27. Santaris Recent Developments and Future Plans
Figure 28. Roche Recent Developments and Future Plans
Figure 29. Global Antisense and RNAi Therapeutics Revenue Share by Players in 2021
Figure 30. Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 31. Global Top 3 Players Antisense and RNAi Therapeutics Revenue Market Share in 2021
Figure 32. Global Top 10 Players Antisense and RNAi Therapeutics Revenue Market Share in 2021
Figure 33. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 34. Global Antisense and RNAi Therapeutics Revenue Share by Type in 2021
Figure 35. Global Antisense and RNAi Therapeutics Market Share Forecast by Type (2023-2028)
Figure 36. Global Antisense and RNAi Therapeutics Revenue Share by Application in 2021
Figure 37. Global Antisense and RNAi Therapeutics Market Share Forecast by Application (2023-2028)
Figure 38. North America Antisense and RNAi Therapeutics Sales Market Share by Type (2017-2028)
Figure 39. North America Antisense and RNAi Therapeutics Sales Market Share by Application (2017-2028)
Figure 40. North America Antisense and RNAi Therapeutics Revenue Market Share by Country (2017-2028)
Figure 41. United States Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Antisense and RNAi Therapeutics Sales Market Share by Type (2017-2028)
Figure 45. Europe Antisense and RNAi Therapeutics Sales Market Share by Application (2017-2028)
Figure 46. Europe Antisense and RNAi Therapeutics Revenue Market Share by Country (2017-2028)
Figure 47. Germany Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Antisense and RNAi Therapeutics Sales Market Share by Type (2017-2028)
Figure 53. Asia-Pacific Antisense and RNAi Therapeutics Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Antisense and RNAi Therapeutics Revenue Market Share by Region (2017-2028)
Figure 55. China Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. South Korea Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Antisense and RNAi Therapeutics Sales Market Share by Type (2017-2028)
Figure 62. South America Antisense and RNAi Therapeutics Sales Market Share by Application (2017-2028)
Figure 63. South America Antisense and RNAi Therapeutics Revenue Market Share by Country (2017-2028)
Figure 64. Brazil Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Argentina Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Middle East and Africa Antisense and RNAi Therapeutics Sales Market Share by Type (2017-2028)
Figure 67. Middle East and Africa Antisense and RNAi Therapeutics Sales Market Share by Application (2017-2028)
Figure 68. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Share by Country (2017-2028)
Figure 69. Turkey Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Saudi Arabia Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. UAE Antisense and RNAi Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Methodology
Figure 73. Research Process and Data Source
Global Targeted RNA Sequencing Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 71
Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing The ability to detect both known and novel gene fusion partners in many sample types.
In The report, we ......
Global Targeted RNA Sequencing Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 87
According to our LPI (LP Information) latest study, the global Targeted RNA Sequencing market size was valued at US$ 1761.4 million in 2023. With growing demand in downstream market, the Targeted RNA Sequencing is forecast to a readjusted size of US$ 7649.2 million by 2030 with a CAGR of 23.3% during review period.
The research report highlights the growth potential of the global Targeted RNA Sequencing market. Targeted RNA Sequencing are expected to show stable growth in the future mark......
Global Targeted RNA Sequencing Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 94
According to our (Global Info Research) latest study, the global Targeted RNA Sequencing market size was valued at USD 1852.7 million in 2023 and is forecast to a readjusted size of USD 7255.4 million by 2030 with a CAGR of 21.5% during review period.
Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or ......
Global Antisense and RNAi Therapeutics Market Research Report 2023, Forecast to 2028
Published: 26-Dec-2023 Price: US 2680 Onwards Pages: 133
Antisense therapy means the selective, sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs in response to dsRNA.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (millio......
Global Antisense and RNAi Therapeutics Professional Survey Report 2023, Forecast to 2028
Published: 26-Dec-2023 Price: US 3280 Onwards Pages: 101
Antisense therapy means the selective, sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs in response to dsRNA.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (millio......
Global Targeted RNA Sequencing Market Research Report 2023, Forecast to 2028
Published: 13-Nov-2023 Price: US 2680 Onwards Pages: 137
Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......
Global Targeted RNA Sequencing Professional Survey Report 2023, Forecast to 2028
Published: 13-Nov-2023 Price: US 3280 Onwards Pages: 100
Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......
Global RNAi for Therapeutic Market Status and Outlook 2023-2028
Published: 08-Nov-2023 Price: US 3160 Onwards Pages: 106
RNAi is a fundamental cellular mechanism for silencing gene expression that can be harnessed for the development of new drugs
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......
Global RNAi for Therapeutic Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 24-Oct-2023 Price: US 3380 Onwards Pages: 104
Market Overview of Global RNAi for Therapeutic market:
According to our latest research, the global RNAi for Therapeutic market looks promising in the next 5 years. As of 2022, the global RNAi for Therapeutic market was estimated at USD 260.55 million, and it's anticipated to reach USD 3633.33 million in 2028, with a CAGR of 55.14% during the forecast years.
RNA interference (RNAi) is a collection of small RNA directed mechanisms that result in sequence specific inhibition of......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
